NKGen Biotech has activated two new trial sites in Canada and Florida for the Phase I/IIa study of troculeucel to treat ...

The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...